阿德福韦酯与拉米夫定联合治疗乙肝肝硬化的临床研究

Clinical Research of the Co-treatment of Adefovir Dipivoxil Combined with Lamivudine on Hepatitis B Cirrhosis

目的探讨阿德福韦酯联合拉米夫定共同治疗乙肝肝硬化的疗效、安全性和耐药性。方法选择乙肝肝硬化患者90例,随机分为三组:A组:联合治疗组30例,口服拉米夫定联合阿德福韦酯各1片;B组:单用拉米夫定治疗组30例;C组:单用阿德福韦酯治疗组30例,均治疗48～96周。结果 A组治疗12、24个月时病毒学应答、治疗12个月时生化学应答与B组、C组比较均有显著性差异(均P<0.01),未发现严重的不良反应。结论阿德福韦酯拉米夫定联合治疗乙肝肝硬化,不易产生耐药性,并具有互补作用,患者能长期稳定病情。

Objective To investigate the co-treatment of adefovir dipivoxil combined with lamivudine of hepatitis B cirrhosis efficacy, safety and tolerability. Methods Ninety patients with liver cirrhosis were randomly divided into 3 groups. A：combined treatment group,30 cases of oral lamivudine plus adefovir dipivoxil each one;B：lamivudine treatment group,30 patients;C：single treatment with adefovir dipivoxil 30 patients. All the patients were treated 48 to 96 weeks. Results The treatment group was 12,24 months,virologic response, treatment for 12 months,biochemical response compared with the control group there were significant differences （all P〈 0.01）,no serious adverse events. Conclusion Lamivudine and adefovir dipivoxil treatment of hepatitis B cirrhosis,drug resistance is not easy,and can play complementaxT roles in long-term stable disease patients.